# A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy

> **NCT07560020** · PHASE2 · NOT_YET_RECRUITING · sponsor: **RyCarma Therapeutics, Inc.** · enrollment: 28 (estimated)

## Conditions studied

- Autosomal Dominant RYR1-Related Myopathy

## Interventions

- **DRUG:** Surlorian
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07560020
- **Lead sponsor:** RyCarma Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2027-08-27
- **Final completion:** 2028-08-27
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07560020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07560020, "A Trial to Compare Treatment With Surlorian (ARM210, S48168) to Placebo in Effects on Muscle Strength and Safety in Adults With Autosomal Dominant RYR1-related Myopathy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07560020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*